GlassScriptPhysician profile
Elizabeth Hedrick
NPI 1225743313
$21,014.53
in general payments reported to CMS, 2019-2025
37 companies · $8,402 in 2025
The $8,402 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $5,204 · 2024: $7,408 · 2025: $8,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,654.61 |
| Education | $359.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,574.91 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $3,537.57 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Axsome Therapeutics, INC. | $2,155.32 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $1,797.30 | 2023-2025 | |
| Harmony Biosciences LLC | $1,356.97 | 2023-2025 | Wakix |
| Mallinckrodt Hospital Products INC. | $1,150.33 | 2023-2025 | Acthar |
| Insmed, INC. | $666.93 | 2023-2025 | Arikayce, Brinsupri |
| Avadel Cns Pharmaceuticals, LLC | $642.45 | 2023-2025 | Lumryz |
| Paratek Pharmaceuticals, INC. | $604.61 | 2023-2025 | Nuzyra, Xhance |
| Verona Pharma, INC. | $409.35 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $394.65 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $363.07 | 2023-2025 | Inspire |
| United Therapeutics Corporation | $346.45 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $306.91 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $298.32 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.29 | 2023-2024 | |
| Viatris Specialty LLC | $254.86 | 2025 | Yupelri |
| Genentech USA, INC. | $223.01 | 2024-2025 | Xolair |
| Grifols USA, LLC | $207.29 | 2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $171.68 | 2023-2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $168.11 | 2023-2025 | Purified Cortrophin Gel |
| Optinose US, INC. | $150.71 | 2023-2024 | |
| Electromed, INC. | $138.36 | 2025 | Smartvest |
| Amgen INC. | $124.79 | 2023-2025 | Tezspire |
| Pulmonx Corporation | $113.04 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.56 | 2023-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Lilly USA, LLC | $87.03 | 2025 | Zepbound |
| Pfizer INC. | $57.80 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $46.06 | 2023-2025 | Horizant, Horizant |
| Inogen, INC. | $34.66 | 2025 | |
| 3b Medical, INC. | $30.36 | 2025 | Luna |
| Philips North America LLC | $29.80 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Resmed Corp | $24.74 | 2024 | |
| Vifor Pharma, INC. | $23.93 | 2024 | Zemaira |
| Tactile Systems Technology INC | $23.58 | 2024 | Flexitouch Plus, Entre Plus |
| Idorsia Pharmaceuticals US INC | $14.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Hedrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.